Alzamend Neuro Inc. (ALZN) - Long-Term Liabilities to Capital

Alzamend Neuro, Inc. (ALZN) operates on an outsourcing model for US-based production, while the lack of commercial products strips the company of pricing power and forces a reliance on equity issuance. The market trend visualized in monetary format on GURU.Markets serves as an indicator, where the metric stands at 0.00. The biotech firm specializes in combating neurodegeneration, yet the absence of revenue prior to the conclusion of testing makes cash flows extremely volatile.

Alzamend Neuro, Inc. (ALZN) invests in ethical biopharmaceutical developments that require significant capital expenditures. This ratio measures the proportion of long-term liabilities relative to equity, determining the degree of financial leverage. It is critical for investors to distinguish excessive debt loads from strategic growth financing. Analyzing the long-term debt-to-equity structure allows for an assessment of the model's sustainability. A reduction in leverage confirms the business's reliability.